As previously reported by Brookfield Brief, Pfizer was looking to acquire the biotech company Seagen Inc. to further the company's capabilities in cancer treatment.

The deal was originally valued at roughly $30 billion but has since then increased to be worth $43 billion.

The new deal will have Pfizer paying $229 a share and is expected to close by the end of the year.

The deal is still under the watchful eye of the antitrust community and will likely face challenges and potential litigation before the deal comes to an end.

Source: Reuters

‍